ALNYLAM REPORTS RSV TREATMENT TRIAL DATA

A A

Alnylam has reported that its lead RNAi product candidate, ALN-RSV01, for the treatment of respiratory syncytial virus infection (RSV), was found to be safe and well-tolerated on intranasal administration in two Phase I clinical studies.

RSV is a highly contagious virus that causes infections in both the upper and lower respiratory tracts. The infection could lead to serious respiratory illnesses like croup, pneumonia, bronchiolitis and death in extreme cases. RSV infections in infants have been linked to the development of childhood asthma.